Conditions: Diabetes Diabetes Mellitus, Type 2
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 687
Healthy volunteers: no

Brief summary:
This trial is conducted in Africa, Asia, Europe and South America. The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg) with insulin glargine (IGlar) in patients with type 2 diabetes. Subjects treated with oral antidiabetic drug(s) (OAD(s)) should continue their current OAD treatment at the stable, prerandomisation dose level and dosing frequency.

Detailed description:

Arms:
arm 1: None arm 2: None arm 3: None

Interventions: intervention 1: insulin degludec intervention 2: insulin degludec intervention 3: insulin glargine
Intervention descriptions: intervention 1: Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted. intervention 2: Injected s.c. (under the skin) once daily. Dose was individually adjusted. intervention 3: Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.

Protocol document: